{
  "meta": {
    "title": "273_Obstetrics_And_Gynecology_Aiims_2019_May_Nov",
    "url": "https://brainandscalpel.vercel.app/273-obstetrics-and-gynecology-aiims-2019-may-nov-32caefb4.html",
    "scrapedAt": "2025-11-30T12:57:42.592Z"
  },
  "questions": [
    {
      "text": "A 40-year-old woman comes with a history of postcoital bleeding and a visible mass seen in the cervix per speculum. The next step to be done:",
      "choices": [
        {
          "id": 1,
          "text": "Conization"
        },
        {
          "id": 2,
          "text": "Cryotherapy"
        },
        {
          "id": 3,
          "text": "Targeted biopsy"
        },
        {
          "id": 4,
          "text": "Pap smear"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>A targeted biopsy</strong> is the next line of management in the patient with a<strong>&nbsp;visible cervical mass </strong>and postcoital bleeding. A <strong>pap smear</strong> is done when there are <strong>symptoms with no identifiable lesion</strong>.</p>\n<p>Other options:</p>\n<p>Option A: <strong>Conization</strong> is an invasive procedure where the <strong>cervix is cut in a cone-shaped manner</strong>. It is both <strong>diagnostic</strong> and <strong>therapeutic</strong>. It&nbsp;is indicated for diagnosis in women with HSIL or adenocarcinoma in situ and may be considered under the following conditions:</p>\n<ul>\n<li><strong>The limits </strong>of the lesion <strong>cannot be visualized</strong> with colposcopy.</li>\n<li><strong>SCJ </strong>(squamocolumnar junction) is <strong>not seen</strong> in colposcopy.</li>\n<li>Colposcopy is <strong>positive</strong> for <strong>CIN 2/CIN 3</strong>.</li>\n<li><strong>Lack of correlation</strong> between cytology, biopsy, and colposcopy.</li>\n<li><strong>Suspected micro invasion</strong> in cytology, colposcopy, or biopsy.</li>\n<li>Colposcopist is <strong>unable</strong> to <strong>rule out</strong> invasive cancer.</li>\n</ul>\n<p>Hence it is very clear that <strong>conization is not indicated for all symptomatic women</strong> and it should be done following either a PAP, colposcopy or a biopsy with an abnormal or inconclusive result.</p>\n<p>Option B: <strong>Cryotherapy</strong> is ideal<strong> only for small superficial lesions</strong>. It&nbsp;is indicated for <strong>biopsy-proven lesions</strong>. Cryotherapy is appropriate for CIN 1 which has persisted for more than 24 months and is confined to the ectocervix.&nbsp;</p>\n<p>Option D: The false negative rate of pap smear in the presence of invasive cancer is 50% and a <strong>negative pap test should never be relied</strong> <strong>on</strong> in a symptomatic patient, especially one with a visible lesion.</p>\n<p>CIN: Cervical intraepithelial neoplasia, HSIL: High squamous intraepithelial lesion, LSIL: Low squamous intraepithelial lesion</p><hr><h3>Related Pearl: Grades of cervical dysplasia</h3><p>A comparison of various naming systems based on cytology (Bethesda) and biopsy (CIN grade)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>WHO grade</strong></td>\n<td><strong>Bethesda</strong></td>\n<td><strong>CIN grade</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>Mild Dysplasia</td>\n<td>LSIL</td>\n<td>CIN I</td>\n<td>Dysplastic cells in basal 1/3 of cervical epithelium</td>\n</tr>\n<tr>\n<td>Moderate Dysplasia</td>\n<td rowspan=\"3\">HSIL</td>\n<td>CIN II</td>\n<td>Dysplastic cells in basal 2/3 of cervical epithelium</td>\n</tr>\n<tr>\n<td>Severe dysplasia</td>\n<td>CIN III</td>\n<td>Dysplastic cells in &gt;2/3 of the cervical epithelium</td>\n</tr>\n<tr>\n<td>Carcinoma in situ</td>\n<td>Carcinoma in situ</td>\n<td>Dysplastic cells in full-thickness of cervical epithelium but basement membrane is intact</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>LSIL</strong></td>\n<td><strong>HSIL</strong></td>\n</tr>\n<tr>\n<td>Atypia confined to the basal one-third of the epithelium</td>\n<td>Atypia involving upper two-third of the epithelium</td>\n</tr>\n<tr>\n<td>80% of LSILs are associated with high-risk HPVs, mostly HPV-16</td>\n<td>100% of HSILs are associated with high-risk HPVs, mostly HPV-16</td>\n</tr>\n<tr>\n<td>60% regress spontaneously; only 10% progress to HSIL.</td>\n<td>30% regress spontaneously; 10% progress to carcinoma</td>\n</tr>\n<tr>\n<td>Not a premalignant lesion</td>\n<td>Premalignant lesion</td>\n</tr>\n<tr>\n<td>Next step - Colposcopic directed biopsy</td>\n<td>Next step -&nbsp;Colposcopic directed biopsy + Endocervical curettage</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Abbreviations:</p>\n<p>CIN: Cervical Intra-epithelial neoplasia</p>\n<p>LSIL: Low Squamous Intra-epithelial Lesion</p>\n<p>HSIL: High&nbsp;Squamous Intra-epithelial Lesion</p><hr><h3>Related Pearl: Management of CIN</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1f5d51f1183f4d35857dd881e7f7f708x1280x1886.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9207",
      "difficulty": "easy"
    },
    {
      "text": "In preterm labor, which drug has a neuroprotective role?",
      "choices": [
        {
          "id": 1,
          "text": "MgSO4"
        },
        {
          "id": 2,
          "text": "Nifedipine"
        },
        {
          "id": 3,
          "text": "Ritodrine"
        },
        {
          "id": 4,
          "text": "Isoxsuprine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>In preterm labor, <strong>MgSO4 </strong>(magnesium sulfate) is considered to have a <strong>neuroprotective</strong> role.&nbsp;Studies have demonstrated that <strong>magnesium exposure</strong> (compared with no exposure) significantly<strong> lowers</strong> the <strong>risks</strong> for <strong>cerebral palsy</strong>.</p>\n<p>The combination of <strong>corticosteroids</strong> and <strong>magnesium sulfate</strong>&nbsp;has been associated with lower rates of neurodevelopmental impairment and death compared to corticosteroids alone.</p>\n<p>The proposed <strong>mechanisms of action</strong> include:&nbsp;</p>\n<ul>\n<li><strong>reduced</strong> <strong>presynaptic release</strong> of <strong>glutamate</strong></li>\n<li><strong>blockade</strong> of glutamatergic <strong>NMDA</strong> receptors</li>\n<li>potentiation of adenosine action</li>\n<li>improved calcium buffering by mitochondria</li>\n<li>blockage of calcium entry via voltage-gated channels&nbsp;</li>\n</ul>\n<p><strong>MgSO4</strong> is used as an <strong>anticonvulsant</strong> in the management of<strong> eclampsia</strong> and as prophylaxis in<strong> severe preeclampsia</strong>. The <strong>therapeutic level</strong> of magnesium in eclampsia is <strong>4&ndash;7</strong> <strong>mEq/L</strong>. Measurement of serum magnesium levels is indicated to monitor magnesium toxicity (if serum creatinine &gt; 1.0 mg/dL).&nbsp;</p>\n<p><strong>Loss of patellar reflex</strong> is the <strong>first sign of MgSO4 toxicity</strong> and occurs when the plasma magnesium level reaches <strong>10 mEq/L</strong>.&nbsp;Elevated magnesium levels above 10 mEq/L <strong>weaken</strong> <strong>breathing</strong>, while<strong> 12 mEq/L</strong> or higher levels can lead to <strong>respiratory paralysis and arrest</strong>.<strong> Other signs</strong> of magnesium toxicity include <strong>urine output &lt;30 mL/h</strong>, chest pain, and heart block visual changes, flushing, muscle paralysis, and drowsiness.&nbsp;</p>\n<p>In suspected toxicity, MgSO4 therapy should be <strong>stopped</strong> and a slow<strong> IV infusion of 1g calcium gluconate 10 mL</strong> (10% solution) is given.&nbsp;</p>\n<p>Other options:&nbsp;</p>\n<p>Options B, C, and D: <strong>Nifedipine</strong> (calcium channel blocker), and <strong>ritodrine, isoxsuprine</strong> (beta-adrenergic agonists) are used as <strong>tocolytics</strong> in preterm labor.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7727",
      "difficulty": "easy"
    },
    {
      "text": "The correct statement regarding the physiological changes in the respiratory system in pregnancy?",
      "choices": [
        {
          "id": 1,
          "text": "Minute volume decreases by 50%"
        },
        {
          "id": 2,
          "text": "Residual volume  increases"
        },
        {
          "id": 3,
          "text": "FRC decreases"
        },
        {
          "id": 4,
          "text": "Total lung capacity increases"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Functional residual capacity</strong>&nbsp;(FRC)&nbsp;<strong>decreases </strong>by<strong>&nbsp;</strong>20 to 30 percent (400 to 700 mL) during pregnancy.&nbsp;</p>\n<p><strong>FRC = Expiratory Reserve Volume </strong>(ERV)<strong> + Residual Volume </strong>(RV). ERV <strong>decreases</strong> by 15 to 20 percent (200 to 300 mL). RV <strong>decreases</strong> by 20 to 25 percent (200 to 400 mL).</p>\n<p>FRC and RV decline due to<strong> diaphragm elevation</strong>. Significant reductions occur by the<strong> sixth month</strong> with a progressive decline across pregnancy.</p>\n<p>The<strong> increased minute ventilation</strong> during pregnancy is influenced by various factors. These include the stimulatory action of progesterone, reduced expiratory reserve volume, and compensatory respiratory alkalosis.&nbsp;<strong>Total lung capacity&nbsp;</strong>(FRC + IC)<strong> decreases&nbsp;</strong>in pregnancy.&nbsp;</p>\n<p><strong>Anatomical changes</strong> such as the elevation of the diaphragm, an increase in the subcostal angle, and an expansion of the transverse diameter of the thoracic cage are seen.&nbsp;</p>\n<p>Respiratory changes in pregnancy are given below:&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Increase</strong></p>\n</td>\n<td>\n<p><strong>Decrease</strong></p>\n</td>\n<td>\n<p><strong>Unaffected</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Tidal volume</p>\n</td>\n<td>\n<p>Functional residual capacity</p>\n</td>\n<td>\n<p>Respiratory rate</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Inspiratory capacity (IC)</p>\n</td>\n<td>\n<p>Expiratory reserve volume</p>\n</td>\n<td>\n<p><br />Vital capacity</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Minute O<sub>2</sub>&nbsp;uptake</p>\n</td>\n<td>\n<p>Residual volume</p>\n</td>\n<td>\n<p>Inspiratory reserve volume</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Minute ventilation</p>\n</td>\n<td>\n<p>Total lung capacity</p>\n</td>\n<td>\n<p>Lung compliance</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Peak expiratory flow rate and&nbsp;airway conductance</p>\n</td>\n<td>\n<p>Total pulmonary resistance</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>(Mnemonic: TIMM increases in pregnancy)&nbsp;</p><hr><h3>Related Pearl: Cardiovascular changes in pregnancy</h3><ul>\n<li class=\"p1\">The resting pulse rate increases by <strong>10 beats</strong>/<strong>min</strong></li>\n<li class=\"p1\">The apex is moved laterally&nbsp;</li>\n<li class=\"p1\">Cardiac output remains elevated throughout (maximum in the immediate postpartum period)</li>\n<li class=\"p1\">X-Ray shows a larger cardiac silhouette (due to benign pericardial effusion and shifted apex)</li>\n<li class=\"p1\">ECG: Slight&nbsp;<strong>left axis </strong>deviation</li>\n</ul>\n<p><strong>Heart sounds:</strong></p>\n<ul>\n<li class=\"p1\">First heart sound: Loud with an exaggerated split</li>\n<li class=\"p1\">Second heart sound: Normal but loud</li>\n<li class=\"p1\">Third heart sound: Loud and easily heard</li>\n</ul>\n<p><strong>Murmurs:</strong></p>\n<ul>\n<li>A systolic murmur<strong>&nbsp;</strong>that was intensified during inspiration or expiration</li>\n<li class=\"p1\">A soft diastolic murmur (in 20%)</li>\n<li class=\"p1\">Continuous murmur&nbsp;arising from the breast vasculature (in 10%)</li>\n</ul><hr><h3>Related Pearl: Hematological changes in pregnancy</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Increases</strong></p>\n</td>\n<td>\n<p><strong>Decreases</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hemoglobin <strong>mass</strong></p>\n</td>\n<td>\n<p>Hemoglobin <strong>concentration</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Total plasma protein</strong></p>\n</td>\n<td>\n<p><strong>S.urea/creatinine/uric acid</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Globulin</strong></p>\n</td>\n<td>\n<p>Albumin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Neutrophils</p>\n</td>\n<td>\n<p>Platelets</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Fibrinogen</strong></p>\n</td>\n<td>\n<p><strong>Blood urea nitrogen</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Factors 7,8,9,10</strong></p>\n</td>\n<td>\n<p>Factor 11,13</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Insulin</strong></p>\n</td>\n<td>\n<p>S.Na/K/Ca/Mg/I<sub>2</sub></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>LDL,HDL,apolipoprotiens</p>\n</td>\n<td>\n<p>-</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>S.Transferrin</strong> and TIBC(Total</p>\n<p>Iron binding capcity)</p>\n</td>\n<td>\n<p>S.Iron, ferritin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>CRP(C-Reactive protein)</strong></p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><strong>Placental phosphatase</strong></p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><strong>Total alkaline phosphatase</strong></p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>ESR 4x rise</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7728",
      "difficulty": "medium"
    },
    {
      "text": "On finding a congenital heart block in a fetus, which of the following conditions would you evaluate for in the mother?",
      "choices": [
        {
          "id": 1,
          "text": "APLA syndrome"
        },
        {
          "id": 2,
          "text": "Congenital heart defects"
        },
        {
          "id": 3,
          "text": "SLE"
        },
        {
          "id": 4,
          "text": "Hemolytic anaemia"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>On finding a <strong>congenital heart block</strong> in the fetus, the mother should be <strong>evaluated for systemic lupus erythematosus </strong>(SLE).</p>\n<p><strong>Fetal</strong> and<strong> neonatal heart blocks</strong> occur due to <strong>myocarditis</strong> and<strong> fibrosis</strong> in the region between the AV node and the bundle of His. Congenital heart block primarily develops in fetuses of women with <strong>antibodies to the SS-A or SS-B antigens</strong>, and up to <strong>50 percent of women</strong> with SLE&nbsp;<strong>test positive</strong> for these antibodies.&nbsp;So in pregnancies with either of these antibodies, <strong>fetal cardiac monitoring</strong> is performed between <strong>18 and 26 weeks</strong> of gestation.</p>\n<p>The <strong>cardiac lesion is permanent</strong>, and in most cases, a <strong>pacemaker</strong> is required.&nbsp;<strong>Maternal hydroxychloroquine</strong> therapy is associated with a reduced incidence of fetal heart block, particularly in women who have previously had an affected child.</p>\n<p><strong>Neonatal lupus erythematosus</strong> is thought to be caused by the&nbsp;<strong>transplacental passage of maternal antibodies</strong>. It is characterized by skin lesions known as<strong> lupus dermatitis</strong> in newborns, as well as various hematological and systemic abnormalities.&nbsp;In some cases, congenital heart block may also occur. Thrombocytopenia and hepatic involvement are also seen.&nbsp;</p>\n<p>The&nbsp;<strong>most common cutaneous finding</strong>&nbsp;in neonatal lupus erythematosus is an erythematous<strong>, slightly scaly eruption</strong>&nbsp;on the&nbsp;<strong>face and periorbital</strong>&nbsp;skin (<strong>raccoon sign</strong>/owl eye/eye mask). The eruption can be&nbsp;<strong>exacerbated by UV exposure</strong>.<strong>&nbsp;</strong>The rash improves over the first few months of life and usually resolves&nbsp;<strong>without scarring</strong>&nbsp;by 12 months of age.</p>\n<p><strong>Avoidance of sunlight</strong>&nbsp;should be advised and&nbsp;<strong>low‚Äêpotency topical steroids</strong>&nbsp;may be of benefit.</p>\n<p>The <strong>pregnancy outcomes are best</strong> in women with:</p>\n<ul>\n<li>&nbsp;Dormant lupus activity for <strong>at least 6 months</strong> before conception</li>\n<li>&nbsp;<strong>No lupus nephritis</strong> manifestation in the form of proteinuria or renal dysfunction</li>\n<li>&nbsp;Absent anti-phospholipid syndrome or lupus anticoagulant&nbsp;</li>\n<li>&nbsp;Superimposed preeclampsia does not develop</li>\n</ul>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7724",
      "difficulty": "medium"
    },
    {
      "text": "A 33 Weeks multigravida woman presents with epigastric pain, headache, visual symptoms, and proteinuria - 3+. The next step of management would be?",
      "choices": [
        {
          "id": 1,
          "text": "Immediate c - section"
        },
        {
          "id": 2,
          "text": "Dexamethasone for fetal lung maturity"
        },
        {
          "id": 3,
          "text": "Induction - vaginal delivery"
        },
        {
          "id": 4,
          "text": "MgSO4 IV"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical scenario of a <strong>33 weeks</strong> pregnant woman with <strong>epigastric pain</strong>, <strong>headache</strong>, <strong>visual symptoms</strong>, and proteinuria 3+ indicates <strong>severe preeclampsia</strong>. The next step of management would be iv<strong>&nbsp;administration of&nbsp;MgSO4&nbsp;</strong>for the <strong>prevention of seizures</strong>.&nbsp;</p>\n<p><strong>Preeclampsia</strong> can be classified as <strong>severe</strong> if <strong>any of the following</strong> are present:&nbsp;</p>\n<ul>\n<li><strong>BP &ge;160/110</strong></li>\n<li>Headache</li>\n<li>Visual disturbance</li>\n<li>Upper abdominal pain</li>\n<li><strong>Elevated creatinine</strong>, oliguria</li>\n<li><strong>Thrombocytopenia</strong> (&lt;1,00,000 cells per mm3)</li>\n<li><strong>Pulmonary edema</strong></li>\n<li>Marked <strong>elevation in serum transaminases</strong></li>\n<li>Fetal growth restriction</li>\n</ul>\n<p><strong>Dexamethasone</strong> (option B) is also given in <strong>severe preeclampsia</strong>&nbsp;&lt;34 weeks for <strong>fetal lung maturity</strong>. But the administration of MgSO4 before corticosteroids would be the next best step for the prevention of seizures.&nbsp;</p>\n<p><strong>Immediate delivery</strong> (options A and C) is <strong>not indicated</strong> in this case as the patient doesn't have any contraindication for conservative management.&nbsp;<strong>Conservative management</strong> is <strong>contraindicated</strong> in the following cases:</p>\n<ul>\n<li>Persistent symptoms, refractory to treatment or severe hypertension</li>\n<li>Eclampsia, pulmonary edema, HELLP syndrome</li>\n<li>Significant renal dysfunction or coagulopathy</li>\n<li>Placental abruption</li>\n<li>Nonreassuring fetal status</li>\n<li>Fetal demise</li>\n<li>Disseminated intravascular coagulation</li>\n<li>Stroke, myocardial infarction</li>\n</ul>\n<p><strong>MgSO4 regimens</strong> for management of eclampsia and severe preeclampsia:</p>\n<table>\n<tbody>\n<tr>\n<td>Regimen</td>\n<td>Loading Dose</td>\n<td>Maintenance Dose</td>\n</tr>\n<tr>\n<td>Intramuscular (Pritchard)</td>\n<td>4g (20% solution) IV over 3-5 minute<br />followed by 10g (5O%), deep IM<br />(5 gm in each buttock)</td>\n<td>5g (5O%) IM 4 hourly in the alternate buttocks</td>\n</tr>\n<tr>\n<td>Intravenous (Zuspan or Sibal)</td>\n<td>4g IV slow over 15-20 minute</td>\n<td>1-2g/h IV infusion</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Magnesium sulfate is <strong>discontinued</strong> either <strong>24 hours after delivery</strong> or <strong>24 hours after the onset of convulsions</strong> (whichever is later).</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/20a6c3215a3540eaad8d2a7485603fa9x557x600.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7725",
      "difficulty": "medium"
    },
    {
      "text": "All of the followings are seen in GDM except:",
      "choices": [
        {
          "id": 1,
          "text": "Malformations"
        },
        {
          "id": 2,
          "text": "Polyhydramnios"
        },
        {
          "id": 3,
          "text": "Fetal Macrosomia"
        },
        {
          "id": 4,
          "text": "Neonatal Hypoglycemia"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Malformations</strong>&nbsp;are <strong>not associated with</strong> gestational diabetes mellitus <strong>(GDM).&nbsp;</strong>Malformations occur due to the <strong>disruption</strong> of <strong>organogenesis,</strong> usually occurring in the <strong>first trimester. </strong>The <strong>abnormal glycemic status </strong>in<strong>&nbsp;GDM</strong> manifests only in the <strong>second trimester</strong>.</p>\n<p><strong>Overt diabetes</strong> (pregestational diabetes) is associated with <strong>higher rates</strong> of <strong>malformations</strong> compared to the general population. <strong>Neural tube defects</strong> (encephalocele, meningomyelocele, anencephaly), <strong>transposition of great vessels</strong> (TGA), <strong>ventricular septal defect</strong> (VSD), <strong>atrial septal defect</strong> (ASD), hypoplastic left heart, aortic stenosis and coarctation of the aorta are commonly seen.&nbsp;&nbsp;</p>\n<p><strong>Caudal regression syndrome</strong> is rare, but a<strong> specific anomaly</strong> seen in infants of diabetic mothers. <strong>Small left colon syndrome</strong> is a rare anomaly that develops in the <strong>second and third trimesters</strong>.&nbsp;</p>\n<p>Other options:&nbsp;</p>\n<p>Option B:&nbsp; In GDM, increased blood glucose in the mother leads to <strong>fetal hyperglycemia</strong>. This can cause <strong>polyhydramnios</strong> due to<strong> increased fetal urine</strong> <strong>production</strong>.</p>\n<p>Option C: Fetal hyperinsulinemia causes increased <strong>hepatic glucose uptake</strong> and <strong>glycogen synthesis</strong>, accelerated lipogenesis, and augmented protein synthesis resulting in<strong> macrosomia</strong>&nbsp;</p>\n<p>Option D: Fetal hyperglycemia in GDM triggers <strong>fetal hyperinsulinemia</strong>, resulting in <strong>neonatal hypoglycemia</strong>&nbsp;</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7723",
      "difficulty": "medium"
    },
    {
      "text": "Hormone replacement therapy is not indicated for:",
      "choices": [
        {
          "id": 1,
          "text": "Hot flashes"
        },
        {
          "id": 2,
          "text": "CAD Prophylaxis"
        },
        {
          "id": 3,
          "text": "Osteoporosis"
        },
        {
          "id": 4,
          "text": "Premature menopause"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Hormone replacement therapy is<strong> not indicated in coronary artery disease prophylaxis</strong>.&nbsp;There is currently <strong>insufficient evidence</strong> to recommend the initiation or continuation of either estrogen therapy (ET) or estrogen-progestin therapy (EPT) for the prevention of primary or secondary coronary heart disease (CHD).&nbsp;</p>\n<p>In an 18-year reevaluation of WHI (women health initiative) participants, it was found that cardiovascular, cancer, and all-cause mortality rates were essentially the same in both the hormone therapy (HT) and placebo groups.</p>\n<p>Currently, <strong>hormone therapy</strong> (HT) is only indicated for the <strong>treatment</strong> of bothersome <strong>vasomotor symptoms</strong> (VMS) and <strong>genitourinary symptoms</strong>, <strong>prevention of osteoporosis</strong>, and <strong>treatment of hypoestrogenism</strong> caused by hypogonadism, surgical menopause, or premature ovarian insufficiency.&nbsp;</p>\n<p><strong>Estrogen should not be used</strong> in women with the following conditions:&nbsp;</p>\n<ul>\n<li>undiagnosed abnormal<strong> genital bleeding</strong></li>\n<li>known, suspected, or history of <strong>breast cancer</strong></li>\n<li>known or suspected <strong>estrogen-dependent neoplasia</strong></li>\n<li>active or prior <strong>venous thromboembolism</strong></li>\n<li>active or prior <strong>stroke, myocardial infarction</strong>, or transient ischemic attack (TIA)</li>\n<li>known thrombophilia, liver dysfunction, or disease</li>\n<li>untreated hypertension</li>\n<li>known hypersensitivity to the ingredients of the estrogen preparation</li>\n<li>known or suspected pregnancy</li>\n</ul>\n<p><strong>Risks of HRT</strong>:</p>\n<ul>\n<li>Endometrial cancer</li>\n<li>Breast cancer</li>\n<li>Ovarian cancer</li>\n<li><strong>Thromboembolism</strong></li>\n<li>Lipid profile dysfunction</li>\n<li>Gall stones, liver dysfunction</li>\n</ul><p>Newer researches and their observations reveal that a few women need prophylactic and therapeutic HRT, but 70&ndash;85% of women remain healthy and need only good nutrition and a healthy lifestyle.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7726",
      "difficulty": "easy"
    },
    {
      "text": "The risk of fetal varicella syndrome is maximum when the mother is infected between _____.",
      "choices": [
        {
          "id": 1,
          "text": "6 to 10 weeks"
        },
        {
          "id": 2,
          "text": "8 to 12 weeks"
        },
        {
          "id": 3,
          "text": "13 to 20 weeks"
        },
        {
          "id": 4,
          "text": "20 to 28 weeks"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The<strong>&nbsp;risk </strong>of developing<strong>&nbsp;fetal varicella syndrome</strong>&nbsp;(congenital varicella syndrome) is <strong>highest&nbsp;</strong>when the mother develops varicella infection between <strong>13 to 20 weeks</strong>.&nbsp;</p>\n<p>Congenital varicella syndrome occurs in <strong>2% of infants</strong> with maternal varicella <strong>between 13 and 20 weeks</strong> of gestation and in<strong> 0.4% of infants</strong> <strong>before 13 weeks</strong> of gestation. It is rare after 20 weeks.</p>\n<p><strong>Congenital varicella syndrome</strong> is characterized by<strong> cicatricial skin scarring</strong> in a zoster-like pattern (zig-zag scarring), and <strong>limb hypoplasia </strong>(shown below). They can also&nbsp;present with <strong>neurological</strong> abnormalities (<strong>microcephaly, cortical atrophy, mental retardation</strong>), ophthalmic features (<strong>chorioretinitis, microphthalmia, cataract</strong>), and renal and autonomic system abnormalities (<strong>hydronephrosis, neurogenic bladder</strong>). <strong>Low birth weight</strong> is also common.&nbsp;</p>\n<p>Infants born to mothers with varicella in the period from<strong> 5 days prior to delivery up to 2 days after delivery</strong>&nbsp;are at high risk for <strong>severe neonatal varicella</strong>. They acquire the infection transplacentally.</p>\n<p>Since the mother has not developed a strong antibody response, the infant lacks the protective effect of maternal anti-varicella-zoster virus (VZV) antibodies.&nbsp; Therefore <strong>varicella-zoster immune globulin</strong>&nbsp;(VZIG)<strong>&nbsp;</strong>should be administered as soon as possible after birth to <strong>newborns</strong> whose mothers have varicella<strong>&nbsp;5 days before and up to 2 days after</strong> the delivery.&nbsp;</p>\n<p>Since perinatally acquired varicella can be potentially life-threatening, the infant should typically be treated with <strong>intravenous acyclovir</strong> (10 mg/kg every 8 hours) when <strong>lesions</strong> <strong>appear</strong>.&nbsp;</p>\n<p>For <strong>pregnant women</strong> with uncomplicated primary varicella or herpes zoster that does not require hospitalization, the recommended treatment is <strong>oral acyclovir</strong>&nbsp;(800 mg five times daily for seven days).&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a9ca7f26f1f745e6b367632ca66f2ddfx383x576.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1593",
      "difficulty": "hard"
    },
    {
      "text": "The loading dose of MgSO4 in pre-eclampsia is?",
      "choices": [
        {
          "id": 1,
          "text": "4 ml Mgso4 (50% w/v) in 16 ml NS"
        },
        {
          "id": 2,
          "text": "8 ml MgSo4 (50% w/v) in 12 ml NS"
        },
        {
          "id": 3,
          "text": "12 ml MgSo4 (50% w/v) in 8 ml NS"
        },
        {
          "id": 4,
          "text": "10 ml MgSO4 (50% w/v)"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p class=\"p1\">The <strong>loading dose</strong> of MgSO4 is<strong> 8ml MgSO<sub>4&nbsp;</sub></strong>(50% w/v) in <strong>12ml NS</strong>. For loading dose IV infusion of <strong>4g of 20% solution</strong> is needed.<strong>&nbsp;</strong></p>\n<p class=\"p1\">One <strong>2mL vial</strong> has <strong>1g </strong>MgSO4. Therefore, to make a 20% solution containing 4g of MgSO4, we would need to take <strong>8 mL </strong>of <strong>50%</strong> magnesium sulfate,&nbsp;and dilute it with <strong>12 mL</strong> NS. Therefore the final 20mL solution (8+12) would have <strong>4g</strong> of MgSO4, making it a 20% solution.</p>\n<p class=\"p1\"><strong>MgSO4</strong> is used as an <strong>anticonvulsant</strong> in the management of <strong>eclampsia</strong> and as <strong>prophylaxis in severe preeclampsia</strong>. The <strong>therapeutic level</strong> of magnesium in eclampsia is <strong>4&ndash;7</strong> <strong>mEq/L</strong>. Measurement of serum magnesium levels is indicated to monitor magnesium toxicity if serum creatinine &gt;1.0 mg/dL.&nbsp;&nbsp;</p>\n<p class=\"p3\"><strong>MgSO<sub>4</sub> regimens </strong>for management of eclampsia and severe preeclampsia:</p>\n<table class=\"t1\">\n<tbody>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\"><strong>Regimen</strong></p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\"><strong>Loading Dose</strong></p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\"><strong>Maintenance Dose</strong></p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Intramuscular (Pritchard)</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">4 g (20% solution) IV over 3-5 minute</p>\n<p class=\"p1\">followed by 10 g (5O%), deep IM</p>\n<p class=\"p1\">(5 gm in each buttock)</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">5 g (5O%) IM 4 hourly in the alternate buttock</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Intravenous (Zuspan or Sibai)</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">4g IV slow over 15-20 minute</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">1-2 g/h IV infusion</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p class=\"p1\"><strong>Repeat injections</strong> of magnesium sulfate are continued only if the <strong>patellar reflex is present</strong>, <strong>respiratory rate is &gt;12</strong>, and <strong>urine output is &gt;30 mL/h</strong>. Magnesium sulfate is <strong>discontinued</strong> either <strong>24 hours after delivery</strong> or <strong>24 hours after the onset of convulsions</strong> (whichever is later).&nbsp;&nbsp;</p>\n<p class=\"p1\"><strong>Loss of patellar reflex</strong> is the <strong>first sign of MgSO4 toxicity</strong> and occurs when the plasma magnesium level reaches 10 mEq/L. Elevated magnesium levels above 10 mEq/L<strong> weaken</strong> <strong>breathing</strong>, while 12 mEq/L or higher levels can lead to<strong> respiratory paralysis and arrest</strong>.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0196",
      "difficulty": "medium"
    },
    {
      "text": "Drug of choice for treatment of pregnant woman with bacterial vaginosis?",
      "choices": [
        {
          "id": 1,
          "text": "Metronidazole"
        },
        {
          "id": 2,
          "text": "Flucanazole"
        },
        {
          "id": 3,
          "text": "Clindamycin"
        },
        {
          "id": 4,
          "text": "Erythromycin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p class=\"p1\">The<strong> preferred treatment</strong> for <strong>bacterial vaginosis in pregnancy</strong> is either <strong>oral metronidazole 500 mg BD </strong><span>for 7 days (or </span><strong>intravaginal</strong><span> </span><strong>metronidazole</strong><span> for<strong> </strong>5 days). Treatment is typically reserved for <strong>symptomatic women</strong>.&nbsp;</span></p>\n<p class=\"p1\"><span>An </span><strong>alternative option</strong><span> is <strong>oral </strong></span><strong>clindamycin</strong><span>, 300 mg BD for 7 days (or intravaginal clindamycin ovules for 3 days).&nbsp;</span></p>\n<p class=\"p1\">Bacterial vaginosis (BV) is characterized by a <strong>decrease in lactobacilli</strong> and an overgrowth of <strong>anaerobic bacterial</strong> species, including <em><strong>g</strong><strong>ardnerella</strong>, prevotella, mobiluncus, </em>and<em> bacteroides.</em> Most women with BV are asymptomatic, but those with symptoms may experience a <strong>foul-smelling, thin</strong> <strong>vaginal discharge</strong>.&nbsp;</p>\n<p class=\"p1\">The clinical diagnosis of BV is based on the presence of<strong> three out of four Amsel criteria</strong>: <strong>elevated vaginal pH</strong> (&gt;4.5), <strong>thin</strong> non inflammatory <strong>discharge</strong>, <strong>&gt;20% clue cells</strong>, and a fishy odor (<strong>positive whiff test</strong>) after adding <strong>10% KOH</strong> (potassium hydroxide) to a vaginal sample.</p>\n<p class=\"p1\">BV is associated with adverse pregnancy outcomes such as <strong>preterm birth</strong>, <strong>preterm premature rupture of membranes</strong>, and <strong>postpartum</strong> <strong>endometritis</strong>. It also increases susceptibility to sexually transmitted infections, including HIV.&nbsp;</p>\n<p class=\"p1\">The image below shows a vaginal epithelial cell, with adherent bacteria (<strong>clue cell</strong>) :&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/39eaeecb56654675b0e004ddebebba7ax510x453.GIF\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0197",
      "difficulty": "easy"
    },
    {
      "text": "A 40-year-old female presented with a history of profuse vaginal discharge. The discharge has a fishy odour. Which of the following best describes the microscopic finding given below?",
      "choices": [
        {
          "id": 1,
          "text": "Epithelial cell with bacteria attached on cell surface"
        },
        {
          "id": 2,
          "text": "Bacteria engulfed by macrophages"
        },
        {
          "id": 3,
          "text": "Neutrophil englufed bacteria"
        },
        {
          "id": 4,
          "text": "Bacteria arranged in clusters"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario of women with fishy odor vaginal discharge is suggestive of <strong>bacterial vaginosis </strong>(BV). The microscopic finding is vaginal&nbsp;<strong>epithelial cells with bacteria </strong>attached to their surface called <strong>clue cells,&nbsp;</strong>creating a poorly defined cellular border. They are the<strong> most reliable indicators</strong> of BV.&nbsp;</p>\n<p>Bacterial vaginosis (BV) is characterized by a decrease in lactobacilli and an <strong>overgrowth of anaerobic</strong> bacterial species, including <em><strong>gardnerella</strong>, prevotella,mobiluncus, </em>and<em> bacteroides</em>. Multiple or new sexual partners, having female partners, and engaging in oral sex are associated with a higher risk of BV. They may experience a<strong> foul-smelling (fishy odor) thin vaginal discharge</strong>.&nbsp;</p>\n<p>The clinical diagnosis of BV is based on the presence of<strong> three out of four Amsel criteria</strong>: <strong>elevated vaginal pH</strong> (&gt;4.5), thin noninflammatory <strong>discharge</strong>, <strong>&gt;20% clue cells</strong>, and a fishy odor (<strong>positive whiff test</strong>) after adding 10% potassium hydroxide to a vaginal sample.&nbsp;creating a poorly defined cellular border.&nbsp;</p>\n<p>BV is associated with adverse pregnancy outcomes such as<strong> preterm birth, preterm premature rupture of membranes</strong>, and <strong>postpartum endometritis</strong>. It also increases susceptibility to sexually transmitted infections, including HIV.</p>\n<p>The <strong>recommended treatment</strong> options in <strong>nonpregnant</strong> women include oral <strong>metronidazole</strong>,&nbsp;metronidazole gel, or clindamycin cream. Alternative options include oral secnidazole, tinidazole, or&nbsp;clindamycin. Partner treatment is not needed.&nbsp;</p><hr><h3>Related Pearl: Named Cells in Histopathology</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Named cells</strong></p>\n</td>\n<td>\n<p><strong>Condition</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Anitschkow or caterpillar cells</p>\n</td>\n<td>\n<p>Rheumatic heart disease</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Globoid cells</p>\n</td>\n<td>\n<p>Krabbe disease</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Kulchitsky cells</p>\n</td>\n<td>\n<p>Small cell carcinoma of lung</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Signet ring cells</p>\n</td>\n<td>\n<p>Signet ring cell carcinoma</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Crumpled tissue paper macrophages</p>\n</td>\n<td>\n<p>Gauchers disease</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Clue cells</p>\n</td>\n<td>\n<p>Bacterial vaginosis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Fried egg cells</p>\n</td>\n<td>\n<p>Oligodendroglioma</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hallmark cells</p>\n</td>\n<td>\n<p>Anaplastic large cell lymphoma</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Shadow cells</p>\n</td>\n<td>\n<p>Pilomatricoma</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Mott cells</p>\n</td>\n<td>\n<p>Plasma cell myeloma</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Lepidic cells</p>\n</td>\n<td>\n<p>Cardiac myxoma</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Spider cells</p>\n</td>\n<td>\n<p>Rhabdomyoma</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Vaginal infections</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Bacterial vaginosis</strong></td>\n<td><strong>Trichomonas vaginitis</strong></td>\n<td>\n<p><strong>Candidal vaginitis</strong></p>\n</td>\n</tr>\n<tr>\n<td>Causative organism&nbsp;</td>\n<td>Altered vaginal flora- increased concentration of <strong><em>Gardnerella vaginalis</em></strong></td>\n<td><strong><em>Trichomonas vaginalis</em></strong></td>\n<td><strong><em>Candida albicans</em></strong></td>\n</tr>\n<tr>\n<td>Aetiology</td>\n<td>Increased vaginal pH</td>\n<td>Sexually transmitted</td>\n<td>Decreased immunity</td>\n</tr>\n<tr>\n<td>Sexual transmission</td>\n<td>No</td>\n<td>Yes</td>\n<td>No</td>\n</tr>\n<tr>\n<td>Discharge</td>\n<td>Fishy, thin, yellow</td>\n<td>Frothy, green</td>\n<td>Curdy, white</td>\n</tr>\n<tr>\n<td>Symptoms</td>\n<td>Fishy odour, no itching</td>\n<td>Itching and burning</td>\n<td>Itching, burning</td>\n</tr>\n<tr>\n<td>pH</td>\n<td>&gt;4.5</td>\n<td>&gt;4.5</td>\n<td>&lt;4.5</td>\n</tr>\n<tr>\n<td>Speculum</td>\n<td>No vaginal epithelium inflammation</td>\n<td>Strawberry cervix</td>\n<td>Inflamed-epithelium</td>\n</tr>\n<tr>\n<td>KOH</td>\n<td>Positive Whiff test</td>\n<td>The whiff test can be positive.</td>\n<td>Pseudohyphae seen.</td>\n</tr>\n<tr>\n<td>Wet mount</td>\n<td>Clue cells. No WBCs seen</td>\n<td>Motile trichomaonads, WBCs seen</td>\n<td>WBCs seen</td>\n</tr>\n<tr>\n<td>Treatment</td>\n<td>Metronidazole or Clindamycin</td>\n<td>Metronidazole, treat&nbsp;partner also</td>\n<td>Oral or vaginal azole, no need to treat partner.</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/459b65517d4548179f9f2082d8210774.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0198",
      "difficulty": "easy"
    },
    {
      "text": "The following instrument is used for _____",
      "choices": [
        {
          "id": 1,
          "text": "VIA"
        },
        {
          "id": 2,
          "text": "VILI"
        },
        {
          "id": 3,
          "text": "PAP smear"
        },
        {
          "id": 4,
          "text": "Colposcopy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p class=\"p1\">The image shown is that of <strong>Ayre&rsquo;s spatula</strong> which is used for preparing <strong>PAP smear</strong>. The Papanicolaou test (Pap test) is a <strong>screening test</strong> for cervical cancer.&nbsp;</p>\n<p class=\"p1\">The <strong>squamocolumnar junction</strong> is scraped using<strong> Ayre's spatula</strong> by rotating it around the cervix. The obtained scrapings are spread evenly onto a glass slide and immediately<strong> fixed</strong> in a solution of <strong>95% ethyl alcohol</strong> and ether. After 30 minutes of fixation, the slide is air-dried and then stained with Pap or a short stain method.&nbsp;</p>\n<p><strong>Prerequisites</strong> for Pap smear testing:</p>\n<ul>\n<li>Should be done prior to vaginal examination.</li>\n<li>Lubricants should not be used.</li>\n<li>The patient should not be menstruating during the pap test.</li>\n<li>The ideal time is around ovulation.</li>\n<li>The patient should not have had intercourse in the 24hrs prior to the test.&nbsp;</li>\n</ul>\n<p><strong>Screening guidelines</strong>:</p>\n<ul>\n<li>Time for initiation: 21 years, regardless of the age of first sexual intercourse.</li>\n<li>Women aged <strong>21-29 years</strong>: <strong>Pap test</strong> <strong>every 3 years</strong></li>\n<li>Women who are aged <strong>30-65 years</strong>: Pap test + HPV testing (<strong>co-test</strong>) every <strong>5 years</strong> or Pap alone every 3 years.</li>\n<li>Women should stop having cervical cancer screening after the age of 65 years. If suspicious PAP, screening till 75 years.</li>\n<li>HIV+ women: annual checkup until three consecutive negative tests followed by testing every 3 years for life.&nbsp;</li>\n</ul>\n<p>Instruments used for Pap smear are given below:&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/246c4a34b6df42cbafedbe3bb8dafd37x1280x4698.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/804cef2985c14f36b2198f3c3bc79154.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0199",
      "difficulty": "easy"
    },
    {
      "text": "Anti-D vaccine is not given in which of the following conditions?",
      "choices": [
        {
          "id": 1,
          "text": "Amniocentesis at 16 weeks"
        },
        {
          "id": 2,
          "text": "Manual removal of placenta"
        },
        {
          "id": 3,
          "text": "Intrauterine transfusion at 28 weeks"
        },
        {
          "id": 4,
          "text": "MTP at 63 days"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The anti-D vaccine is not given in<strong>&nbsp;intrauterine transfusion at 28 weeks</strong>. Intrauterine transfusion is done in <strong>alloimmunized</strong> pregnancies, where the maternal immune system (Rh negative) has already been exposed to the fetal blood (Rh positive).</p>\n<p>The purpose of the anti-D vaccine is to prevent the development of maternal antibodies against fetal red cells, which is already occurring in alloimmunized pregnancies.&nbsp;</p>\n<p><strong>Anti-D vaccine</strong> is <strong>administered</strong> only in <strong>ICT-negative non-isoimmunized</strong> pregnancies.</p>\n<p>Intrauterine transfusion is done when the&nbsp;<strong>peak systolic velocity</strong> of the middle cerebral artery (MCA)<strong> exceeds 1.5 multiples of the median</strong>&nbsp;or if <strong>hydrops</strong> develop or if the fetal <strong>hematocrit is &lt;30%</strong>.&nbsp;This indicates that the <strong>mother already has antibodies against the fetus's red blood cells</strong>, making the administration of anti-D unnecessary.&nbsp;</p>\n<p>The <strong>indications for administering anti-D</strong> are:</p>\n<ul>\n<li>Pregnancy loss: <strong>spontaneous or elective abortion</strong>&nbsp;(option D) and ectopic pregnancy.</li>\n<li><strong>Fetal death</strong>: Regardless of the trimester.</li>\n<li>Procedures: Such as <strong>amniocentesis </strong>(option A), <strong>chorionic villus sampling</strong>, fetal blood sampling, and molar pregnancy evacuation.</li>\n<li>Other situations: Antepartum bleeding (including threatened abortion), delivery (vaginal or cesarean), external cephalic version, placental abruption, <strong>manual removal of</strong> <strong>placenta</strong> (option B), and trauma to the abdomen during pregnancy.&nbsp;</li>\n</ul>\n<p>All Rh D-negative women should be given a single dose of 300 mcg of <strong>anti-D at 28 weeks</strong> of pregnancy (ICT should be negative).&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/4413ce522e1a41d2b88fec6e0c6b0cf9x1280x3281.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0200",
      "difficulty": "hard"
    },
    {
      "text": "What does this tocograph show?",
      "choices": [
        {
          "id": 1,
          "text": "Deceleration"
        },
        {
          "id": 2,
          "text": "Acceleration"
        },
        {
          "id": 3,
          "text": "Normal"
        },
        {
          "id": 4,
          "text": "Deceleration followed by acceleration"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given topograph shows a <strong>drop in fetal heart rate below the baseline</strong> indicating <strong>decelerations</strong>.&nbsp;Deceleration is the <strong>decrease in fetal heart rate</strong> below the baseline by 15 bpm for more than 15s.&nbsp;</p>\n<p>Following are the various types of decelerations seen on CTG and their clinical significance:&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td>Feature</td>\n<td><strong>Early deceleration</strong></td>\n<td><strong>Late deceleration</strong></td>\n<td><strong>Variable deceleration</strong></td>\n</tr>\n<tr>\n<td>The pattern of heart rate fall</td>\n<td>The maximum dip of the deceleration corresponds with the peak of the contraction.&nbsp;</td>\n<td>Onset, maximum dip, and recovery occur after the onset, peak, and recovery of contraction respectively</td>\n<td>\n<p>Abrupt fall&nbsp;in the heart rate.&nbsp; &nbsp;</p>\n<p>Decelerations are variable in respect of the size, shape, depth, duration, and timing of uterine contractions.</p>\n</td>\n</tr>\n<tr>\n<td>Time taken to reach the maximum dip of deceleration</td>\n<td>&gt;30seconds</td>\n<td>&gt;30seconds</td>\n<td>&lt;30 seconds</td>\n</tr>\n<tr>\n<td>Cause</td>\n<td>Fetal head compression</td>\n<td>Fetal hypoxia due to maternal hypotension, placental insufficiency, and excessive uterine activity</td>\n<td>Umbilical cord compression</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>The CTG given below shows a <strong>sinusoidal pattern</strong>. It resembles a <strong>sine wave</strong>. It is often associated with <strong>fetal anemia</strong>, fetomaternal hemorrhage, and fetal acidosis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/023d5e1868084c37b924d4e51fb13096x600x630.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Deceleration patterns on cardiotocography (CTG)</h3><p><strong>Early deceleration</strong>: seen in head compression</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/01ca2f6239b443139c19f8cfb251123fx720x612.JPEG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<p><strong>Late deceleration</strong>:&nbsp;Seen in uteroplacental insufficiency, foetal hypoxia</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d22f1efb031f427abc29cb814976ea47x468x323.JPEG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<p><strong>Variable</strong> <strong>deceleration</strong>: Seen in umbilical cord compression</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/034553eba0b7498882645a4cf156f0e0x468x399.JPEG\" alt=\"Pearl Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/14141c8e343e4c0aa14bdf6589f1bb7a.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0201",
      "difficulty": "easy"
    },
    {
      "text": "A 16-year-old unmarried female has come to the gynecology OPD for cervical cancer vaccination. Which vaccine is preferred?",
      "choices": [
        {
          "id": 1,
          "text": "Gardasil"
        },
        {
          "id": 2,
          "text": "Biovac"
        },
        {
          "id": 3,
          "text": "Rabivac"
        },
        {
          "id": 4,
          "text": "Tvac"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p class=\"p1\"><strong>Gardasil</strong> is a vaccine administered to provide <strong>protection against cervical cancer</strong>.</p>\n<p class=\"p1\">Gardasil is a <strong>quadrivalent vaccine</strong> providing protection against <strong>HPV serotypes 6,11,16</strong> and<strong> 18</strong>. It can be given to both <strong>males</strong> and <strong>females</strong> and provides protection against anogenital warts, CIN (cervical intraepithelial neoplasia), and Ca cervix.&nbsp;</p>\n<p class=\"p1\">Types of available HPV vaccines:&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td>Brand name</td>\n<td><strong>Cervarix</strong></td>\n<td><strong>Gardasil</strong></td>\n<td><strong>Gardasil-9</strong></td>\n<td><strong>Cervavac</strong></td>\n</tr>\n<tr>\n<td>Characteristic and HPV subtypes</td>\n<td>Bivalent:16,18</td>\n<td>Quadrivalent: 6,11,16,18</td>\n<td>Nonavalent: 6,11,16,18,31,33,45,52,58</td>\n<td>Quadrivalent: 6,11,16,18</td>\n</tr>\n<tr>\n<td>Protects against:</td>\n<td>CIN<br />CA cervix</td>\n<td>Anogenital warts<br />CIN<br />CA cervix</td>\n<td>Anogenital warts<br />CIN<br />CA cervix &nbsp;<br />Vulval intraepithelial neoplasia<br />Vaginal intraepithelial neoplasia<br />Anal cancer<br />Oropharyngeal cancer<br />Head and neck cancers</td>\n<td>Anogenital warts<br />CIN<br />CA cervix<br />&nbsp;</td>\n</tr>\n<tr>\n<td>Dose</td>\n<td>0.5 ml, IM.</td>\n<td>0.5 ml, IM.</td>\n<td>0.5 ml, IM.</td>\n<td>&nbsp;0.5 ml, IM.</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p class=\"p1\"><strong>Cervavac</strong> is <strong>India's first indigenously prepared</strong> <strong>quadrivalent HPV</strong> (qHPV) <strong>vaccine</strong> against HPV strains 6, 11, 16, and 18.&nbsp;</p>\n<p>As per the December 2022 WHO updated dose schedules on HPV vaccines, the recommendations for different age groups are as follows:&nbsp;</p>\n<ul>\n<li class=\"p1\"><strong>1 or 2 doses</strong> schedule for the primary target of girls aged <strong>9&ndash;14 years</strong>.</li>\n<li class=\"p1\"><strong>1 or 2 doses</strong> schedule for young women aged <strong>15&ndash;20 years</strong>.</li>\n<li class=\"p1\"><strong>2 doses</strong> with a 6-month interval for women<strong> older than 21 years</strong>.</li>\n<li class=\"p1\"><strong>3 doses (or at least 2 doses)</strong> for<strong> immunocompromised</strong> individuals/HIV infected.</li>\n</ul><p>Other options:</p>\n<p>Option B:&nbsp;<strong>Biovac A</strong> is a freeze-dried live attenuated vaccine indicated for the prevention of<strong> hepatitis A</strong> in persons of age 1 year or older.</p>\n<p>Option C:&nbsp;<strong>Rabivac</strong> is a monovalent<strong> inactivated rabies vaccine</strong> for cats and dogs.</p>\n<p>Option D:&nbsp;<strong>Tvac</strong> is a <strong>Tetanus vaccine</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0202",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following agents cause hydrops fetalis?",
      "choices": [
        {
          "id": 1,
          "text": "CMV"
        },
        {
          "id": 2,
          "text": "Parvovirus"
        },
        {
          "id": 3,
          "text": "Toxoplasma"
        },
        {
          "id": 4,
          "text": "HIV"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Parvovirus B19</strong> is the most common<strong> infectious cause</strong> of nonimmune&nbsp;<strong>hydrops fetalis</strong>. Parvovirus B19 infects fetal erythroid progenitor cells and causes anemia. Severe anemia leads to <strong>high-output cardiac failure</strong> and <strong>nonimmune</strong>&nbsp;<strong>hydrops fetalis</strong>.&nbsp;</p>\n<p><strong>Hydrops</strong> is diagnosed by identifying <strong>two or more fetal effusions</strong>, such as pleural, pericardial, or ascitic effusions, <strong>or</strong> the presence of one effusion along with anasarca. Hydrops can be seen in association with red cell auto immunization, which is termed <strong>immune hydrops</strong>. Otherwise, it is <strong>nonimmune</strong>.&nbsp;</p>\n<p><strong>Nonimmune hydrops is more common</strong> than immune hydrops. <strong>Causes of nonimmune hydrops</strong> include <strong>cardiac pathology</strong> (Ebstein anomaly), <strong>chromosomal</strong> (Turner's syndrome), <strong>hematological</strong> (hemoglobinopathies), lymphatic abnormalities (cystic hygroma), and thoracic abnormalities.&nbsp;</p>\n<p><strong>Infectious causes of nonimmune hydrops</strong> are <strong>p</strong><strong>arvovirus B19</strong> (most common), <strong>syphilis</strong>, <strong>cytomegalovirus</strong>, <strong>toxoplasmosis</strong>, rubella, enterovirus, varicella, herpes simplex, coxsackievirus, listeriosis, leptospirosis, Chagas disease, and Lyme disease.&nbsp;</p>\n<p>The following image shows a stillborn baby with hydrops fetalis:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e9b7aa613458483ab89a517a5d95318cx241x415.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0203",
      "difficulty": "medium"
    },
    {
      "text": "The given instrument is used in:",
      "choices": [
        {
          "id": 1,
          "text": "Vaginal hysterectomy"
        },
        {
          "id": 2,
          "text": "Cesearean section"
        },
        {
          "id": 3,
          "text": "Manchester operation"
        },
        {
          "id": 4,
          "text": "Fothergill's surgery"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The image shown is that of a <strong>Doyen's retractor&nbsp;</strong>which is&nbsp;used in <strong>caesarean sections</strong>.</p>\n<p class=\"p1\">It is used to <strong>retract the abdominal wall</strong> as well as the <strong>bladder</strong> for proper exposure of the lower uterine segment during cesarean&nbsp;sections.</p><hr><h3>Related Pearl: Identification of Surgical Retractors</h3><p><strong>Deaver's Retractor:</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1bdb9c3f1d64405eb0ba5d6b7f14c373x800x600.JPEG\" alt=\"Pearl Image\"><p><strong>Doyen's retractor:</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/ba4b0fd005ca49eb9e1bd9f3a014a99dx1280x960.JPEG\" alt=\"Pearl Image\"><p><strong>Morris retractor:</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/20f77217c4f6464189079798ee63679fx714x340.JPEG\" alt=\"Pearl Image\"><p><strong>Czerny&rsquo;s retractor:</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f080538ebecb4e22bb229bfcafd32caax720x390.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: Instruments in OBG</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/59138be1e8d141fe9ebaef4f7e659432x1181x870.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/733db2f903e2492a86c5426c9474709bx1280x938.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1d44522851ed42ec8da170d61c415f12x1159x933.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8cbd2117a78e4c31a4487cddaa43a2c2x871x617.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/6d38c784ac734fa3ace7fd390520778ax880x699.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/47aee7f73b87421a9faa3402828666bfx953x721.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/072c8ca058fd4f4d92e6ae299cfdbd04x735x592.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/05dc8444e062403f8c826a7ad52c00d9x759x574.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f40b790592224b05ac1d680696b5c5bcx806x609.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2af70bdfbb4f4253992b9813d001f51dx800x600.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/42a06419caad4e8bb379998dfc73f30cx953x691.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1260a318cf0049718c5175a47f084400x855x654.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/46a8dbc68e894ba8b91d4c14d19b515ex771x677.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/4b753a73ddde4ea2acc7c461fb7292a8x762x739.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/26a35cac6bd747bf957fed883a1fd850x922x638.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/91c0754e8b4846c0a6325cbf2e4f8721x1203x701.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/12052a1ae2a64be6937c40bbc4009652x750x705.JPEG\" alt=\"Pearl Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/13aefb3ae0e54fc89b5101ad0b3f1003.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0204",
      "difficulty": "easy"
    },
    {
      "text": "A case of gestational trophoblastic neoplasm is detected to have metastasis in the lungs. It is considered as stage _____.",
      "choices": [
        {
          "id": 1,
          "text": "I"
        },
        {
          "id": 2,
          "text": "II"
        },
        {
          "id": 3,
          "text": "III"
        },
        {
          "id": 4,
          "text": "IV"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Metastases in the&nbsp;<strong>lungs</strong> are considered stage <strong>III</strong>&nbsp;GTN (gestational trophoblastic neoplasia) in FIGO classification.</p>\n<p>International Federation of Gynecology and Obstetrics (FIGO) staging for GTN is as follows:</p>\n<table>\n<tbody>\n<tr>\n<td>Stage</td>\n<td>Description</td>\n</tr>\n<tr>\n<td>I</td>\n<td>GTN confined to the <strong>uterus</strong></td>\n</tr>\n<tr>\n<td>\n<p>II</p>\n</td>\n<td>\n<p>GTN extends outside of the uterus but is limited to the <strong>genital</strong> structures &nbsp;&nbsp;&nbsp;</p>\n<p>(adnexa, vagina, broad ligament)</p>\n</td>\n</tr>\n<tr>\n<td>III</td>\n<td>GTN extends to the <strong>lungs</strong>, with or without known genital tract involvement</td>\n</tr>\n<tr>\n<td>IV</td>\n<td>All <strong>other</strong> metastatic sites i.e. kidney, liver, brain, bowel, etc.</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>The chest X-ray below shows lung metastasis - stage III GTN.&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/9b4129c54c0840fb8c61afc93bbfc840x600x487.JPEG\" alt=\"Explanation Image\"><p><strong>Gestational trophoblastic neoplasia</strong> (GTN) refers to the aggressive invasion of the endometrium and myometrium by <strong>trophoblast cells</strong>. It includes <strong>invasive mole</strong>, <strong>gestational</strong> <strong>choriocarcinoma</strong>, <strong>placental site trophoblastic tumors</strong>, and<strong> epithelioid trophoblastic tumors</strong>. GTN is diagnosed based on elevated &beta;-hCG levels. FIGO criteria for diagnosis of GTN:&nbsp;</p>\n<ul>\n<li>Persistence of <strong>&beta;-hCG level plateau</strong> in <strong>4 measurements</strong> for 3 weeks or longer</li>\n<li><strong>Rise in &beta;-hCG</strong> levels in <strong>3 or more consecutiv</strong>e measurements done <strong>weekly</strong>, over a period of 2 weeks or longer</li>\n<li><strong>Elevated &beta;-hCG</strong> level for <strong>6 months</strong> or more</li>\n<li><strong>Histologic diagnosis</strong> of choriocarcinoma&nbsp;</li>\n</ul>\n<p>Treatment for <strong>low-risk disease</strong> is chemotherapy with <strong>methotrexate</strong>, while those with <strong>high-risk disease</strong> are treated with etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (<strong>EMA/CO</strong>) chemotherapy.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a322b86670814b4e944a4e24b787e1cdx1279x2253.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9862",
      "difficulty": "medium"
    }
  ]
}